image credit- freepik
Japan-based Meiji Seika Pharma Co. has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organisation.
Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR).
GHIC has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to leverage venture capital investments to accelerate the development and introduction of technologies and medical products that respond to and prevent health security threats. Through this public‑private partnership, GHIC launched GHSF, a pioneering venture capital fund dedicated to supporting innovations that strengthen public health preparedness and build resilient global health systems capable of detecting, preventing, and responding to future public health emergencies.
“Investing in GHIC’s GHSF was a straightforward decision for us,” said Toshiaki Nagasato, President and Representative Director of Meiji Seika Pharma. “GHIC’s mission to address unmet global health needs closely aligns with Meiji Seika Pharma’s long‑standing commitment to infectious disease innovation. We are pleased to participate in GHSF as a limited partner and to collaborate with GHIC’s highly experienced team. Together, we aim to drive meaningful impact in areas such as infectious diseases, where unmet medical needs remain substantial but sustained pharmaceutical engagement has been limited due to challenging market dynamics.”
